Angiotensin II blockade may reduce risk of skin carcinoma

kavin submitted, created time 4 months 2 days (www.oncolink.org)

Use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) appears to lower the incidence of basal cell and squamous cell carcinoma among people at high risk, according to a study among U.S. veterans.

Evidence from in vivo and in vitro studies suggests that angiotensin II is a potent angiogenic and growth factor, Dr. Jennifer B. Christian and co-investigators note in the September 3 Journal of the National Cancer Institute, issued online on August 26

2 comments | Blog It | Email It | Keywords: oncology Angiotensin-converting enzyme human renal cell carcinoma renal cell carcinoma cancer skin cancer angiotensin merkel cell carcinoma

CD4(+) T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25(+) T cells

Immunology submitted, created time 1 year 1 month (www.ncbi.nlm.nih.gov)

BACKGROUND: The human 5T4 (h5T4) oncofoetal antigen is expressed by a wide variety of human carcinomas including colorectal, ovarian, gastric and renal, but rarely on normal tissues. Its restricted expression on tumour tissues as well as its association with tumour progression and bad prognosis has driven the development of a MVA-based vaccine (TroVax) which has been tested in several early phase clinical trials and these studies have led to the start of a phase III trial in renal cell carcinoma patients

Submit comment | Blog It | Email It | Keywords: kidneys RCC T-cells immunology cancer 5T4 T regulatory cells human renal cell carcinoma human renal cell carcinoma (RCC) CD4+ T cells